Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI1SXB)

• Drug Name: Rafabegron Drug Info
• Synonyms: AD-9677; AJ-9677; TAK-677

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 5493324
  CAS Number: CAS 244081-42-3
  TTD Drug ID: DMI1SXB

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor beta-3 (ADRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mirabegron	DMS1GYT	Overactive bladder	GC50.0	Approved	[3]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[4]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[5]
Bopindolol	DMIFYLX	Hypertension	BA00-BA04	Approved	[6]
Mepindolol	DMUDWP9	Angina pectoris	BA40	Approved	[7]
Rimiterol	DMA47C6	Asthma	CA23	Approved	[8]
Bitolterol	DMK6XAV	Chronic obstructive pulmonary disease	CA22	Approved	[9]
Nipradilol	DMA65ER	Angina pectoris	BA40	Approved	[10]
Vibegron	DMFR201	Overactive bladder	GC50.0	Approved	[11]
ONO-2506	DMCA2PJ	Stroke	8B20	Phase 2/3	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-3 (ADRB3)	TTMXGCW	ADRB3_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009164)
• [2] Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled ran... J Clin Endocrinol Metab. 2007 Feb;92(2):527-31.
• [3] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [4] Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
• [5] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [6] Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
• [7] Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
• [8] Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
• [9] Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
• [10] Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [12] FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.